Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Life Sciences Industry in China (China)

This article was originally published in PharmAsia News

Executive Summary

China's life sciences industry has grown steadily by 16.1 percent per year between 1978 and 2005, and by 19.4 percent during the past five years, to become a $51.8 billion industry in 2005. Chinese life sciences companies have dented the dominance of Western synthetic drug products in China, with Western products falling from 60 percent of the market in 2000 to 54 percent today. China's life sciences industry carries a low profitability margin of 8.12 percent in 2000 and 8.45 percent in 2005 because of tough competition, extremely tough generic drug competition, and downward pressure on drug prices from governmental authorities. Chinese research and development spending has expanded by 28 percent during the last four years to reach 1.02 percent of total sales in 2005, an amount far below the 15 percent or more of sales that Western companies redirect into pharmaceutical research. China's aging population and increasing frequency of chronic diseases means that Chinese demand for medicine will grow. China's government plans to promote over-the-counter drugs and also increase market investment in research and development to a goal of 2 percent of sales by 2010, and 2.5 percent of sales by 2020. China's main competition is India, and China's drug regulatory framework remains unclear and too bureaucratic. IMS Heath states that China in 2005 had a $29.6 billion total market for chemical and synthetic raw medicines, and a $12 billion market for over-the-counter and ethical pharmaceuticals, with traditional Chinese medicines representing a third, popular category. (Click here for more

You may also be interested in...

WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.

Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses

Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts